Sorafenib in Previously Treated Malignant Mesothelioma
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The principal objective of the study is to investigate the effect of sorafenib on progression
free survival (time until the cancer begins to grow again,) in patients with malignant
mesothelioma who have had prior treatment with chemotherapy. Effectiveness of the drug will
also be explored with PET scans before and during treatment.